Polycythaemia after renal transplantation.

Ann Acad Med Singap

Department of Haematology, Singapore General Hospital.

Published: April 1987

The haematological, biochemical and clinical features of six patients with polycythaemia after renal transplantation were studied. The patients had an absolute increase in red cell mass, but normal plasma and whole blood volumes. Primary proliferative polycythaemia was excluded. Polycythaemia developed within one year of transplantation and persisted for 3-7 years. Chronic rejection, renal artery stenosis, severe hypertension and corticosteroid therapy were probably not the cause of the polycythaemia. There were no occlusive vascular lesions during the observation period and venesections were generally not required. The polycythaemia is probably the result of the cumulative production of erythropoietin by the donor and recipient kidneys.

Download full-text PDF

Source

Publication Analysis

Top Keywords

polycythaemia renal
8
renal transplantation
8
polycythaemia
6
transplantation haematological
4
haematological biochemical
4
biochemical clinical
4
clinical features
4
features patients
4
patients polycythaemia
4
transplantation studied
4

Similar Publications

POEMS Syndrome.

Presse Med

January 2025

Department of Hematology and Cellular Therapy, National Reference Center "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposit Diseases, University Hospital of Limoges, Limoges, France.

POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin changes) is a syndrome that involves a monoclonal B-cell proliferation, most often plasmacytic, and a variable number of manifestations listed or not in the acronym. These manifestations include sclerotic bone lesions, plasmacytic Castleman disease, papillary edema, peripheral edema, ascites, thrombocytosis and/or polycythemia, venous and/or arterial thrombosis, and renal, pulmonary, and cardiac impairments . Diagnosis is often delayed due to the rarity of this entity and its clinical polymorphism, which can mimic other neurological disorders.

View Article and Find Full Text PDF

We herein report a 56-year-old man with severe hypocalcemia during ruxolitinib therapy for myelofibrosis transitioning from JAK2 mutation-positive polycythemia vera. Blood transfusions were administered every one to two weeks for ruxolitinib-induced anemia. Blood tests revealed hypocalcemia with low TRACP-5b, 25-hydroxyvitamin D (25 (OH) D), and 1,25-dihydroxyvitamin D (1,25 (OH) D) levels within the lower reference range.

View Article and Find Full Text PDF

Introduction: Polycythemia is a rare condition that can be either primary or secondary. We report a case of an adolescent with progressive hydronephrosis-induced polycythemia and low erythropoietin levels, along with a thorough literature review.

Report Of A Case: A 17-year-old girl with epilepsy had progressively elevated hemoglobin levels and low erythropoietin levels.

View Article and Find Full Text PDF

Coexistence of tubulocystic renal cell carcinoma and polycythemia vera: A rare case report.

Int J Immunopathol Pharmacol

December 2024

Department of Urology and Pelvic surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Tubulocystic Renal Cell Carcinoma (TC-RCC) and Polycythemia Vera (PV) are both infrequent medical conditions. TC-RCC was recognized as a distinct subtype of kidney cancer by the World Health Organization in 2016, while PV is a rare myeloproliferative neoplasm distinguished by the excessive production of red blood cells. The coexistence of these two conditions is exceptionally uncommon and lacks comprehensive documentation.

View Article and Find Full Text PDF

Effect of therapeutic erythrocytapheresis on outcomes and renal benefit in patients with high-altitude polycythemia: a real-world study.

Sci Rep

November 2024

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Kidney injury from high-altitude polycythemia (HAPC) is common, yet few studies have explored effective treatments. This research assessed the renal benefits of therapeutic erythrocytapheresis (TE) in HAPC patients, analyzing the efficacy of single versus multiple treatments. From 2017 to 2023, 631 patients undergoing TE were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!